TP53 and cancer: In the current study we found by examining the SULF2 methylation in 100 gastric cancer samples, that the rate of SULF2M was approximately 30%, which indicated that predominate gastric cancer were SULF2U. Recent studies by integrated genomic analyses revealed that SULF2 acts as a downstream effector of p53, and that activation of p53 could lead to the SULF2U and up-regulation of SULF2. The possible link between p53 and SULF2 in growth factor signaling pathway suggested a possible role for SULF2 in cancer development and cancer patients’ outcome [25].